Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Carcinoma, Squamous Cell
/ drug therapy
Chemoradiotherapy
Cisplatin
/ administration & dosage
Docetaxel
/ administration & dosage
Female
Gingival Neoplasms
/ drug therapy
Humans
Infusions, Intra-Arterial
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
Treatment Outcome
head and neck cancer
intra-arterial chemotherapy
maxillary gingival squamous cell carcinoma
oral cancer
radiotherapy
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
06
08
2018
revised:
20
10
2018
accepted:
10
12
2018
pubmed:
30
1
2019
medline:
11
11
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy. A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed. Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC.
Sections du résumé
BACKGROUND
The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy.
METHODS
A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m
RESULTS
The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed.
CONCLUSIONS
Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC.
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1777-1784Informations de copyright
© 2019 Wiley Periodicals, Inc.